Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Labcorp, NowDx collaborate to expand rapid syphilis testing

September 2025—Labcorp and NowDiagnostics are collaborating to expand access to rapid syphilis testing. The companies will distribute First to Know Syphilis Test kits at no cost to select community-based public health organizations across the United States. Labcorp and NowDx distributed kits to more than 15 organizations across the country, including to LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics. Labcorp serves as the exclusive commercial laboratory offering the test for health care providers as well as directly to consumers

New England Biolabs launches NEBNext library prep kit

September 2025—New England Biolabs launched the NEBNext Low-bias Small RNA library prep kit, designed to minimize biased representation of small RNA species in sequencing data. A novel splint adaptor increases the diversity of interactions, facilitating ligation and increasing sensitivity, with a streamlined, simplified protocol. As a result, researchers can analyze all RNA species present in biologically relevant samples. Standard and 2’-O-methylated samples can also be processed using the same protocol, with multiplexing enabled through up to 480 compatible unique dual index primer pairs (available separately). Total workflow time is approximately 3.5 hours and the shelf life is 18 months.

Illumina launches TruSight Oncology 500 v2 research assay

September 2025—Illumina has launched TruSight Oncology 500 version 2, the next generation of the company’s flagship pancancer next-generation sequencing assay that enables in-house comprehensive genomic profiling from formalin-fixed, paraffin-embedded tissue for oncology research. A key enhancement of the new assay is fully integrated homologous recombination deficiency analysis included for every sample, powered by a gold-standard genomic instability scoring algorithm licensed from Myriad Genetics. Other updates include more sensitive variant calling and improved coverage of difficult genomic regions. The new kit has 50 percent less packaging and 70 percent fewer tubes.

Qiagen, Incyte to develop CDx for patients with myeloproliferative neoplasms

September 2025—Qiagen is collaborating with Incyte to develop a novel diagnostic panel to support Incyte’s portfolio of investigational therapies, including Incyte’s monoclonal antibody INCA033989, for patients with myeloproliferative neoplasms. Under the terms of the master collaboration agreement, Qiagen will develop a multi­modal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the Illumina NextSeq 550Dx.

ArteraAI Prostate gets breakthrough device designation

September 2025—The FDA has granted breakthrough device designation to Artera’s ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer. ArteraAI Prostate analyzes digital pathology images of a patient’s prostate cancer biopsy slide to prognosticate long-term outcomes, such as 10-year risk of distant metastasis and prostate-cancer specific mortality, to help clinicians determine the most appropriate treatment option.

Cepheid gets Health Canada license for Xpert HIV-1 Viral Load XC

September 2025—Cepheid has received a medical device license from Health Canada for its Xpert HIV-1 Viral Load XC, a next-generation extended-coverage test intended to aid in assessing HIV viral load levels. The test is designed for use on the company’s GeneXpert systems.

Copan announces leadership transition in medical and scientific affairs

September 2025—Copan Diagnostics has appointed Hema Kapoor, MD, D(ABMM), as director of medical and scientific affairs for the Americas, succeeding Susan Sharp, PhD, D(ABMM), who will retire this month following more than three decades of distinguished service to clinical microbiology. Dr. Sharp joined Copan in 2018, after a career spanning more than 30 years as a clinical microbiologist, educator, and industry leader. She previously served as chief of microbiology at Kaiser Permanente and held leadership roles at the American Society for Microbiology, including chair of the committee on laboratory practices and past president. A diplomate of the American Board of Medical Microbiology and fellow of the American Academy of Microbiology, Dr. Sharp has been recognized with ASM’s highest clinical honor, the BioMérieux Sonnenwirth Award, and the ABMM Professional Recognition Award. At Copan, her leadership has been defined by keen insight and a steadfast advocacy for advancing microbiology.

SehaMed, New Day Dx to launch ColoHealth in the Middle East

September 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East. Under the terms of the agreement, SehaMed will leverage its network of distributors across the Gulf Cooperation Council to introduce ColoHealth.

IDT unveils infectious disease research solutions

August 2025—Integrated DNA Technologies has unveiled its PrimeTime influenza kit and PrimeTime research pathogen panels. The influenza kit is a qPCR solution designed to amplify common influenza strains and targets influenza A, influenza A (H5N1), influenza B, and RNase. It includes an internal control for sample quality assessment, a premixed primer and probe set, PrimeTime 4x Broad-Range Master Mix, and direct amplification enhancer.

SSI Diagnostica acquires Gulf Coast Scientific

August 2025—SSI Diagnostica Group is acquiring Gulf Coast Scientific (Oldsmar, Fla.), which specializes in the development of urea breath testing for Helicobacter pylori, to further strengthen its gastrointestinal disease testing portfolio. SSI Diagnostica, headquartered in Denmark, acquired CTK Biotech (Poway, Calif.) in 2020 and TechLab (Blacksburg, Va.) in 2022. Jointly the group will have a total revenue of approximately $125 million.

MARKETPLACE

TRENDING